No profile data available.
Kiromic BioPharma, Inc. (KRBPQ) is a healthcare company in the additional cancer treatment drugs industry, based in Houston, United States, with about 44 full-time employees.
It reported revenue of $0 for fiscal year 2024, and net income of -$33.73 million. Its market capitalization was $265 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 8, 2026.
, a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States.
Kiromic BioPharma reported $0 in revenue for fiscal year 2024.
$265 as of October 8, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Affimed N.v. (AFMDQ), Panbela Therapeutics, Inc. (PBLA), eFFECTOR Therapeutics, Inc. (EFTR), LadRx Corporation (LADX).